CESARE DI BARI, M.D.; GIUSEPPE PASTORE, M.D.; GEORGIO ROSCIGNO, M.D.; PAUL J. SCHECHTER, M.D., Ph.D.; ALBERT SJOERDSMA, M.D., Ph.D.
To the editor: Human trypanosomiasis is a major public health problem in many African countries. At present, there is alarm at the recrudescence of this disease in its historical habitats. Melarsoprol, an organic arsenical and the only agent currently available to treat the late-stage disease (that is, with meningoencephalic involvement), is associated with a high incidence of toxicity (up to 10% mortality) (1, 2), and a growing percentage of cases of late-stage trypanosomiasis are now refractory to treatment (3). We are aware of several cases of trypanosomiasis recently seen in the United States and Europe.
Eflornithine (DL-alpha-difluoromethylornithine), an inhibitor of
BARI CD, PASTORE G, ROSCIGNO G, SCHECHTER PJ, SJOERDSMA A. Late-Stage African Trypanosomiasis and Eflornithine. Ann Intern Med. 1986;105:803–804. doi: 10.7326/0003-4819-105-5-803_3
Download citation file:
Published: Ann Intern Med. 1986;105(5):803-804.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use